Trouble reading this e-mail? View it in your browser.

EFPIA
Newsletter
12 December 2014
Header
Header image
Highlight of the week

News

Pharmaceutical Sector Association EFPIA Welcomes Joe Jimenez, CEO of Novartis, as New President
09 December 2014

 (9 December 2014 – Brussels): EFPIA is pleased to announce today the official appointment of Joe Jimenez, CEO of Novartis, as its new President, following [...] Read more

News

News

Research and Generic/Biosimilar Industries Join Forces against Counterfeiting
09 December 2014

(9 December 2014 - Brussels): EFPIA, the European Federation of Pharmaceutical Industries and Associations, and EGA, the European Generic medicines Association, are pleased to announce [...] Read more

News

EFPIA Responds to Commission’s 5th Report on the Monitoring of Patent Settlements with a Proposal for Increased Transparency of Key Medicines Patents to Facilitate Early Resolution of Patent Disputes
08 December 2014

(8 December 2014 - Brussels): The 5th monitoring report of patent settlements released by DG Competition on 5 December 2014 notes a continued increase in the [...] Read more

From our blog

From our blog

The light of day is the best disinfectant
11 December 2014 by Richard Bergström

In 1891, Louis Brandeis, who later served as judge on the US Supreme Court, wrote: “If the broad light of day could be let in upon men’s actions, it would purify them as the sun disinfects”. He later expressed this idea as “the light of day is the best disinfectant”. 

Read more

Events calendar

Events Calendar

“Development Pathways for Advanced Therapy Medicinal Products”
On 15/12/2014 (London, UK )

3rd Edition – A workshop organised by EBE in collaboration with European Medicines Agency and the Italian Embassy’s Scientific Office in London Chairs: Eduardo Bravo, EBE Vice President [...] Read more

What we are reading

What we are reading

Tell me the whole story: the role of product labelling in building user confidence in biosimilars in Europe
11 December 2014 (Tell me the whole story: the role of product labelling in building user confidence in biosimilars in Europe)

This paper reviews the need for sufficiently detailed and transparent labelling and product information (PI) regarding biosimilars to enable informed decision making by physicians and patients and therefore ensure appropriate safe and effective use of the medicine. The authors, representing the European Biopharmaceutical Enterprises (EBE), argue that it is necessary to ensure that the evidentiary basis and terms of approval for each biosimilar and its reference product are clear, and so they set out a proposal for transparency concerning evidence generated for these respective products. 

Read more

About EFPIA updates
Unsubscribe to be removed from this mailing list | Update your subscription

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 34 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.
Leopold Plaza Building
Rue du Trône 108
B-1050 Brussels (Belgium)
Tel: +32 (0)2 626 25 55
E-mail: communications@efpia.eu
Follow EFPIA
Twitter LinkedIn Youtube Google + Pinterest E-mail